Khiron combines its patient-centric approach with continuing education and training for physicians to improve access to cannabinoid-based therapies for patients worldwide. To date, the company has trained nearly 1,000 medical professionals in Latin America and the UK, together with partners like the Medical Cannabis Clinicians Society (MCCS) and the school of medicine of the Tecnologico of Monterrey (TecSalud).
Khiron’s portfolio of cannabinoid-based medicines in Europe is steadily expanding to include full-spectrum extracts, in addition to various cannabis flos in the near future. The company is pursuing a consistent approach to improve patient access to medical cannabis and to develop the market for medical cannabis treatments in the UK.
With the opening of Zerenia™ Clinics UK, a specialized medical cannabis clinic in London, the company is pursuing a consistent approach to improve patient access and to develop the market for medical cannabis treatments in the UK, which started in 2019 when Khiron became a founding member for Project Twenty21, offering a subsidized pricing model to help address barriers to access in the UK market.